Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JB-101 for induction of operational tolerance in living donor liver transplantation
jRCT2073200067Phase 2Active, not recruiting
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Jan 2020
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of JB-101 in hepatic disease and hepatic failure, sponsored by Japan Agency for Medical Research and Development. Primary endpoint: Operational tolerance rate. Started Jan 2020; status: active, not recruiting.
02
Drugs
JB-101
03
Conditions
hepatic diseasehepatic failure
Beyond the preview
Go deeper on jRCT2073200067.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2073200067.